Home Cancer Symptoms Regeneron pays Sanofi $900M for full rights to cancer drug Libtayo as it looks to become a force in oncology

Regeneron pays Sanofi $900M for full rights to cancer drug Libtayo as it looks to become a force in oncology

by admin
0 comment

Regeneron will pay Sanofi $ 900 million for all rights to the anticancer drug Libtayo, as it appears to help oncology

You may also like

Leave a Comment

Blue__white_and_green_Medical_care_logo-removebg-preview (1) (2)

HealCancer is the best newspaper and magazine website with tons of news articles and information about cancer and its facts and symptoms and research as well. This website is dedicated to spread awareness about the illness and help better understand and deal with it, visit our home page for more news .

Editors' Picks

Latest Posts

HEALCANCER – All Right Reserved.